In patients that received magrolimab plus AZA, CR/CRi rate in the TP53 mutant AML patients receiving treatment was 78% overall, with a pronounced reduction in TP53 mutant variant allele frequencies, spotlighting Magrolimab as a candidate for frontline therapy in cytogenetically unfavorable AML patients with T53 mutants. Here, TP53 is linked to acute myeloid leukemia.